Ann: December 2023 Quarterly Activity Report and Appendix 4C, page-9

@Techs - The 4c seems to have caused you some real concern. I am not sure about others but I am pretty sanguine about it, the reasons for the cash draw are well understood and many of the factors are one off in nature and without other metrics, such as AR, it is very difficult to put that number in to context.

I don't think they will need more cash but I am confident if they do it will be a very small amount and pretty easy to raise either via debt or equity. If the FDA were to knock back the Xpreica approval then I would agree with you that change is required. However, If it gets approved, as it should in the couple of months, then I think many of your concerns should evaporate.

Overall, I want UBI to carry on doing what it is doing, in the medium term that is how it will maximise returns and hopefully the share price.